Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilars Deals 2023
Diversity
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
PipCast®
PTE
Trade Marks
Webinars

Home / News / BioBlast® / Biosimilar Deals 2018

EXPLORE OUR

Biosimilars Deals 2018

Explore our interactive biosimilar news updates, collating tailored reports by brand, INN, originator/biosimilar applicant, litigation, region, or date. Alternatively, review our weekly BioBlast updates below.

Biogen and Samsung Bioepis close asset transfer for Biogen share increase

Biogen and Samsung Bioepis close asset transfer to increase Biogen’s share in Samsung Bioepis to 49.9%. This deal originates from the initial creation of Samsung Bioepis and the partnership between Biogen and Samsung BioLogics, in which Biogen was granted an option to increase its share in the company, expiring in mid 2018.

US-Mexico-Canada Agreement exclusivity period raises concerns

US-Mexico-Canada Agreement includes 10 year exclusivity period for biologic drugs, raising concerns that competition will be hindered to the disadvantage of consumers and health services in those regions. Currently the exclusivity period stands at 8 years in Canada and 5 years in Mexico.

BioSciences Corp and Mab-Venture announce development/commercialisation deal

Californian HQ’d BioSciences Corp & Shanghai based Mab-Venture announce a deal under which Mab-Venture will develop and manufacture biosimilars and BioSciences Corp will commercialise (through partners) those products in India, SAARC, MENA, Turkey, LatAm and Russia. The deal covers “multiple” products which have not been named.  Read more